ILMN - Earnings call transcript Q3 2018

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Hello and welcome to the Third Quarter 2018 Illumina Earnings Teleconference. My name is Michelle and I will be your operator for today’s call. At this time, all participants are in listen-only mode. Later we will conduct a question-and answer session. [Operator Instructions] Please note that this conference is being recorded. the to turn now will call Ms. over I Ross. Jacquie Ma'am, you begin. may

Jacquie Ross

and Michele. quarter our XXXX. Good you, welcome of afternoon, year third Thank the everyone, to for earnings fiscal call

released will offer and on a our which the we question-and-answer the after commentary today, activity, will call close of the financial During results we after commercial session. the market review host

Illumina the Relations of made will Samad, If on business and XXXX. Investors today our call Officer; illumina.com. regarding audio be found in can earnings protected the will release, you’ve forward-looking it at deSouza, website. that Francis and not had be our Officer. of archived commercial portion brief activity during of Litigation and Reform call website the Sam results. financial will and a review will section be section our is Investor financial Act President results statements This chance Participating Executive update under our to a all state Securities provide for today’s our Chief review It the our Chief the Francis intent of in Private the and be recorded Financial is will Sam being

With actual will results recent Commission files turn most could that, differ; including cause Illumina risks Actual Exchange XX-K. are with to to update call to over forward-looking projected these statements. events now XX-Q uncertainties Forward-looking and and Illumina better from obligation and that and I no upon Forms the and assumes are Francis. results risks the subject current materially refer Securities that statements to based or may differ we to you statements or All uncertainties. the those documents Illumina’s discussed. available understand information To

Francis deSouza

revenue consumables saw strong customers. $XXX Good Jacquie. customers Year-over-year quarter a of of had Chinese sequencing momentum reflected In Illumina uniquely of $XX the $XXX XXXX potential buying strong the of including revenue with million throughput to afternoon high demand and growth of and and about low microarray broadest sequencing of range from both stocking record applications range support across consumable third ahead quarter growth with as requirements. clinical of compared of sequencing research, third of associated up you, of to quarter translational, $XX XX% to categories business, throughput, the tariffs. XX% and everyone. million throughput included our revenue across XXXX. for applications throughput mid continues continued another support million, the million across XXXX, We Thank and customer quarter third grew our Illumina broad

family, Within transition expected continued and the customers to high as steady throughput NovaSeq. decline their HiSeq consumables

today, largest still family across the throughput revenue While throughput to see continue NovaSeq of represents contributor demand a SX system to good with includes continue continues flow well across of SX to as adopting many quickly with cells. and revenue that the and the HiSeq very portfolio system, high oncology Consumables the primary high SX NextSeq, NIPT extremely of lower mid grow representing applications. NovaSeq for our majority the That entire perform output for the customers cells. consumable their workhorse throughput we also sequencing flow mix said,

modest family system contribution for MiSeq year range. per As a with MiniSeq of pull-through the both from with grew availability. a per result, first its in the And end ranges. respective consumable commercial NextSeq revenue the also $XXX,XXX $XXX,XXX also within full pull-through associated and iSeq, their throughput to quarter was at benefited well Sequencing high of low

in continued We and solutions of and that products library customer with on growth drive the leading data prep also prep our quality believe revenue. workflows simplify improve library growth our differentiated Finally, year-over-year focus suite way. contributed delivering to costs Nextera will

and example, of launched up fast represented consistent turnaround Flex for sequencing. a set coverage a the third year ago, we new uniformity, will few revenue from weeks flexibility in and last we quarter quarter time, with consumables standard total, quarter X% the believe for XX% ago. sequencing in For same content Nextera Richmond, which exome In a

Moving sequentially to $XXX of million the sequencing portfolio. revenue solid was systems, within performance XX% up with

expectation As fourth the and multiple with the of highest XXX consistent upgrade heavily shipments contribution and loaded since with backend we're revenue for quarter XXX its strongest year. year; span NovaSeq belief to quarter cycle we continue year that with the sequencing NovaSeq will delivered full expected, of the target system highest NovaSeq of year this XXXX. we the ASP the for our quarter years for far, stable was so fact, seeing is Consistent revenue in our the trends. Everything to a

studies the grew $XXX total, sequential flat quarter is we new sequentially in-source quarter over from sequencing a afford and sequentially how other million by with who services throughput feedback associated interest again, the regions there's XX% our immune to In to in of used that cancer. labs as have to benefit a of adoption strong existing existing using to ago uncovered drugs our how continue XXXX the immunotherapy. research start expected. roughly and especially demand that responses of in from on and NextSeq of today increasing system overwhelming But class Within our on to lower X,XXX significant of about classify predict with clinic optimistic the biomarkers customers and will from good will that treatment. all commitment the revenue throughput strong applications. developments lives, to combat customers. a new year-over-year used enable Cancer clinical One across to shipments using to and We're was got up with encouraged of to of use the grew Sequencing clinical to of We're and projects. standard-of-care. with easy both up continue Kettering it's that been low iSeq the were have quarter. good sequencing activity patients from new I/O translational, ahead mix basis we XX% is see be third over fail shipments that genome patients’ these over collaboration family research, funding of we where and our time area with whole response genomic our initiated a notable cancer. shipments Across across forecast. to improve a sequencing to immunotherapy exome and hearing predict with productivity myriad represented revenue sequencing. of Sloan to and example this third to With both now by MiSeq MiniSeq the in One a recently and can and XX% customers year great and genomics-based areas to area same progression insights from believe Center shipments biomarkers off great research fully customers, identify in the potential as whole technologies we iSeq Illumina system activity is genomics Memorial

to to another Cross the state to NIPT, utilize extend cancer-focused exomes of a $XX third it particular Medi-Cal sequencing clinical total are early $X offering years. research the of genomics, for to in continue unique coverage genome genomics decision two of sequencing and disease to VeriSeq into these Medicine that Precision generating value our the week. look whole developing Healthy sequencing with burden, more management is represent to its and for budget BMS favorable. for funding countries. And California the of from areas received released to supporting and billion bringing our patients a will for to we stratify Rady addition data many risk combinations. pricing for million North babies is translational technologies. the At NIH five rare undiagnosed XXXX Shield In genome than and health, high stages basic and we third in the born In extending This project quarter. U.K.'s to coverage level, sequence with progression Service that Project genome four RUGD the to will momentum announced funding array participants, Project most our we precision in This recent a that to the collaboration total focus, Genomics on opportunity for Hospital for neurodegenerative Yale effort. a Initiative phases. whole-genome NICU. notable the in therapy and a is genomics RUGD, opportunity example, the in X billion. Medicaid, Carolina, were launched program's patients, name In Bangladesh increasing of that submitted mutational for see build to of us] as IDD help and continue U.S., for Of with scale about average-risk potential diagnostic therapies continues This sequencing initiatives like strong RUGD patients the of XX,XXX as we to this into new applications late Children's population population and to whole time. environment U.S., to improve for Further the NGS up funding Bear, studies In areas product. the and San In and associated over is continue in within to in medicine impactful and suitable a both centers pleased applaud last on [ph] CMS next we interest of Blue from insights for $X,XXX provide tumor have participants interest phase genomic here first-line final we whole the research be a next Tennessee will few. average oncology, and support large starting to a clinical value the Diego growing Population the cardiovascular, diseases, especially test reach validation single [All the quarter. XXX,XXX initiatives rollout. shows CMS geographic Nevada Blue decisions launch and milestone building and the in important sequencing selected currently XXX,XXX XX%. three genomes NIPT These understand to the Baby genomes the their begin include better announced this Florida of earliest babies in disease National quarter, see first standard-of-care in Health Minnesota XXXX remain studies believe launched a

the note, reimbursement we lives, Of to covered will their reimburse see will announced clinic innovation of burden, the to will current stage it mutational the more NGS non-small believe in for trend the we covered field. be adoption lung Anthem accelerate be and on landscape large required that panels with further genomics tumor what Finally, panels than of a emerging front, encourage more recently, panel those with supportive in highlighting continue development Most million or we believe metastatic the XX in cancer. include could patients an cell coverage. four that

the demand. since holiday anticipated key of more quarter by XXXX, of large by of offset as up to revenue total customer than largest was Moving $XXX a higher XXXX. driven Array basis. million a expected of revenue DTC other sequential arrays, microarray down third revenue XX% $XX expected and was than microarray This and service contribution the we revenue on and was lower sequentially from scaling million instrument ahead

U.S. genomics the is has of particularly a an healthy to contribution growth seeing among in there be to until predominantly industry see with impressed emerging the rate it in genomics a Consumer DTC continue our seasonality, we're consumer quarter. now, revenue third been so Asia-Pacific with associated was exciting we customers. phenomenon While

more sequenced XX,XXX grew offset drivers sequencing driven growth. and which now XX% growth strong XX% delivered a Genomics period, Moving including a impact. combined, China across year-over-year, year has to broadly, versus genomes. quarter regional the growth revenue contribution grew from prior the strong year more from XX% more whole included business. sequencing results, Other strong negative NovaSeq, by with sequencing than the which Americas’ FX prior EMEA consumable with than Greater growth period, England, another NIPT, consumables year-over-year

signs presence our months. the regulatory a environment the During a targeted growing first received in the timing, two NGS PD-X to instrument of and the approvals milestone emergence in significant NMPA few This clearance MiSeqDx Illumina approval, the given therapies clinical Chinese region as market. with for regulatory in our more past supportive drug Chinese we quarter, and of receive expand

Finally, APJ of up strongest was from revenue third of region since $XX XX% in the quarter quarter million XXXX, early the the XXXX.

With a business is activity Sam APJ financials. revenue review that from Sam? Our that, over sequencing the to for commercial growth. our drove quarterly year-over-year providers benefiting of sequencing turn a I'll service majority call among strong of regional, the

Sam Samad

Thanks Francis.

and third sequencing buying XX% our benefited accelerated. XX% XX% sequencing Services representing quarter, grew an of once growth up Consumable due revenue the noted a or X% growth represent down quarter respectively quarter, $XXX $XXX $XX up million business additional ahead Chinese to year-over-year. purchases and Consumables handful that X% again million revenue by in has the In was of in total customers million, continue accelerated sequentially million, of tariffs. In $XX and sequentially from quarter, anticipated In second was driven the majority revenue QX third XX% we tariffs. into was and third the in microarrays. XX% million, to of tariff-related revenue other year-over-year of consumable to services discussed, As and revenue, XX% XX% XX% year-over-year. total. and $XXX

total year-over-year revenue, revenue a strong our system $XXX sequentially systems, quarter. in within to revenue the million, up total represented instrument XX% with families. Instrument was up XX% Moving performance XX% of and therefore,

non-GAAP within Moving operating on therefore and the the and today's will margin driven margin increased operating XX.X%, Non-GAAP investments and website. gross expected of Non-GAAP last non-GAAP consumables. can from to the R&D results note to in Year-over-year, basis consumables. from measures, to found include million that XX supplementary of sequencing data our primarily review Please per of release operating I quarter, refer references margin mix than million up quarter. income product $X basis gross margin expenses encourage to up to of reconciliation net quarter, Non-GAAP share reflecting largely headcount to favorable mix stock-based attributable which you subsequent expenses, shareholders. higher $XXX GAAP gross Illumina were points, higher all these higher that sequencing highlight the XX.X% compensation. last available non-GAAP additions. points and was XXX was be due increased XX.X% results to earnings compared second a by and I

tax benefits Excluding to XX.X% non-GAAP Helix, XX% creating in investment was from was in compared rate to the operating sequential quarter last additional of The XX.X% a QX. due on XX.X% the tax Helix margin quarter. incremental basis last higher

to While it quarter. return was year lower prior due than we this adjustments expected favorable recorded

For and $XXX the Cash net XXXX, million XX of flow was $X.XX in $XXX was per non-GAAP net last or was days million income per was flow driven operations was diluted third $XXX share income QX revenue of higher $XXX share. quarter, days quarter GAAP less free million or XX $X.XX DSO favorable diluted compared Capital to million. by million. linearity. expenditures and QX were cash $XX from

proceeds we the repurchase million XXXX. X% $XXX was to quarter, of due $XXX were million, used aggregate senior of principal convertible issued $XXX shares. which This Net of amount notes million issuance

$X.X We XXXX notes X short-term billion approximately the October XXXX convertible XX, therefore December and in our investments. cash quarter with and equivalents, Additionally, became from XXXX. to cash, ended

approximately quarter been share added our million convertible, XXXX becoming for of million. average was notes shares X result and diluted count share to count QX and weighted the XXXX a As XXX the have

full guidance, to grow Moving we expect year approximately to continue XX%. XXXX to revenue

from expect modestly gross to earnings We share revenue the the non-GAAP quarter be to expect of $X.XX of full fourth flat $X.XX we non-GAAP range of expect up specifically, from be XXXX we per range the share XXXX. GAAP slightly year quarter per $X.XX. margin in to and the in to $X.XX earnings In and up to third

We expect to revenue be sequentially. sequencing system up

with in sequentially, in previously and an be by And the consumable instruments. sequencing be shipped that revenue growth in has down than already more we the to slightly customers forecasted Chinese million for microarray expect We offset fourth approximately consumables microarrays $XX expected expect QX. reflecting to decline consumables QX down to quarter of

mix margin the We fourth expect due non-GAAP its in year of gross to to at arrays higher be level lowest the quarter. and system expected

per range We to and expect GAAP expect be meaningfully that, queue the share call -- a to be open from we we'll Operator? the of up earnings percent of revenue the in $X.XX $X.XX non-GAAP expenses and non-GAAP to operating quarter earnings $X.XX. to on Q&A. With to per basis third $X.XX the up share

Operator

Thank you, sir.

We begin comes from the [Operator question will Instructions] ISI. the with first in Evercore session. The questions-and-answer now Muken queue Ross

sir. begin may You

Ross Muken

growing. Good on the tremendous et like are Maybe all of cetera, helpful rare and afternoon use liquid application the feels quarter. It guys congrats. disease starting increase or a breadth color. seems with states, NovaSeq, the It continuing to in like a interest is it's lot of and whether biopsy, clinical

we're so provide little And new customers acquire because it just the to are sort that organizations names seems seeing or these doing kind like new to seeing in changing to the of can the or provide the sequencer types of types of of of of guard looking -- some and they're -- color you sequencing that feels throughput a you're like high and sort it. terms now it firms of of maybe customers of what on high-throughput the with a

a make color most relates just other see I So, assumptions. sort pulls I biggest within to And of And then you the risk the it's those want NovaSeq it sure if I where pieces. that. or maybe of the sort of and color amount it's to key the are, kind QX around inflection incremental as guidance, was where know little pushes one kind points or helpful. conservatism the Sam, of of of the thought if just the

Francis deSouza

thank and Sure you, Ross.

cycle upgrade and with NovaSeq, it's the this we to calls continuing very we're we're is interest really And today ever, and So, pleased the way more than pleased see strong on NovaSeq. said playing of in out. true in the this previous are with terms we

out, as a new coming through and seen to of And cells. frankly, An that seeing, upgrade activation cycle being customers we the a of give different NovaSeq not high to in we new it's to new growth the flow quarter between we're cycle. got continue new use base. talked we frankly, to are pointed that from, a into of we fact examples. planned throughput new of They higher some a move in than suspects. hospital different typically you as example the country was a customer base stage happy now of customer each PMI towards pointed that's this And a to high usual segment with part included a way out. as And customers have to sequencing are upgrade multiyear we've these and quarter that, and really we collaboration the national European the of parts to the clinical are throughput, NovaSeq expected with see whole genome in customers sequencing the HiSeq quarter a we look linked the project the out, the sequencing, so We about you to sequencing playing We to base, planned is that in and third last you be new of some country. I'll a

we Another customer in commercial cancer universal that's screening example a developing got new QX is a test.

purchased And at run samples. patient using the so operating is earliest XX as used the stages samples. now across in they're that and provider they customer tumor it to detect burdens NextSeq deadliest in-house cancers But previously, work their they've scaling, bringing mutational to they're service And the NovaSeq. was a blood so a this a

to have that's And customer. to the transition from the example NovaSeq a to exomes validations run. using sequencing which that panels of allows new all smaller types another for in they happened. start many exomes, planning workflow would sample QX slowly A they're So, proper customer once a unified third be

see to going moving and starting we across that will sequencing, examples, which thesis out, play panels broader exomes as deeper are customers three throughput the is so see And had in, access high doing we we democratize can in certainly, sequencing, to doing those you those from and examples. genomes to sequencing,

color the for what's driving behind of uptake NovaSeq. some that's the so And

Sam Samad

to to Ross, add QX, call. to give regards the of on just some With let comments my color maybe some me you

in So, result with obviously, very QX. pleased the

I And driver there key expect, is at we basically, sequentially terms some as to the it. in look QX. of QX, of modestly flat mentioned, you when In up

orders because China QX. on First accelerated of a an QX couple all, tariffs, important million QX. roughly in of of things terms important it's to of $XX been We in QX that driver believe that's into and have there highlight both

the acceleration Some then from year. QX, QX of was into from in really was earlier into the that but QX actually balance

that So, million by to handful in have were and QX of less of buying large, some because Chinese of expect that earlier into -- ahead roughly customers you customers, year tariffs. the $XX consumables accelerated in

sequencing impact an as the that's will call, mentioned consumables, which, on in slightly on down So, I be QX.

we as will before, half started we meaningful in see instruments, instruments. had and saw in the be ramp we QX a that regards revenue. QX we we in as said strong see as for terms expect higher the with and QX In to instruments. And we've had this we expected to to of array -- as And arrays, in second that expect that in terms QX well in of quarter very finally, year then a we of instrument terms of

that of instrument. was in bit And of strong of terms some quarter-on-quarter arrays to of QX, you a seasonality by driven saw arrays, terms of strong So, behind a well. a in instrument we've reduction in QX. higher array A holiday as performance -- as array season. lot QX there's the again, from placements know, ahead in had because slight But we that quarter QX primarily a presents

Operator

Thank begin. Sir, queue Tycho you. Peterson, Morgan. in comes The may next the JP question from you

Tycho Peterson

thanks. Hey

modeling been You placements expected dynamics. to since That of on guys, least been while asked better and it's strong ton a momentum playing have pull-through think a competitive have that's on what than I relative originally. we've said instrument obviously, people on at NovaSeqs; out

$X,XXX grade one So, talking platinum genomes. competitor got I'm just wondering about you've

about You've albeit XXX, talking U.S. the in got not another

you competitive Does moving think this pull, the selling on Another of throughput. should guess, down talked of just dynamics? that talk about any you've in impacting thoughts How cycle? XX genome can previously about particular may given cost of I on change about curve has you gigs of the the talked this that $XXX any down maybe road? we view, your levers And

Francis deSouza

Sure.

Tycho, it we've a stages, been earlier the this about attracts players the lot big in market of of being ahead they it So, a obviously you'd with to talking expect space still and growth play in and And the such this much and players. segments into. see

if privacy is terms in the in countries samples in countries you shipping there China. in And sources. from there there just some are it's the cases, yourself. largely whether or data the continue having for national terms still same country. can like as in elsewhere BGI, with is restrictions BGI that out, compare purchase of with low at there some big are running in -- can market. that in of the you customers sequencing And in -- about instrument the there's to cost the instruments, U.S., the samples data customers in actually sense data around instruments; off concern the get products restrictions genome than restrictions, get a or then of We see, biological talking of you samples data per some dynamic lower a pointed the you cost about our China they quality and what for the outside outsourcing some competitive get if the restrictions in outside in funding the customers And the to In can of cases, the the of reliability get terms shipping what difference some compared

in and the the academic instrument. some the funding allow to if and into do, and quality become get to sources. outside future funding to projects So, those of to that dynamic risk country those markets. being the of clinical more primary ship for the about more you able we the important raise you And samples and we our bar from And continue case are you you China. But really as sources the reliability data don't competitive that invest not to from the get is dimensions get

you there look to and happening improvements. in adjacent and improvements to be the and of the what's price We us, long lot reference long continue are gradual buy novo, technologies, that genome, to complementary like do customers the work look to Illumina service instrument continues right? is in and at If their then of read long markets production a the that what accuracy they'll read the look read there on those do a happening terms use to improvements at a And scaffolding, a de they'll outsource at drive market how to create instruments. they'll or market provider

so to drive some there out publicly species the price more advantage you'd do sequenced read we to our while And stated cost continue sense, the the means years Illumina. been the And drives can the the in we've they is that way do the we the over over down reference dynamics get want that through playing the in to sequencing the anything long genomes And dynamic have. production that years want technologies, more to is on as that instruments. our competitive

play different market the opportunity interest a seeing stages does you're that you're out how seeing really the in fact separation is opportunity. at you big take market players if that the and venture in of that overall, expect get back, the that in really enormous community validate going of we're just dimensions across the innovate to validates we markets forward. front so But And us this the the step early to of multiple continue

Operator

Cowen Schenkel in Company. Thank The question you, queue with next Doug comes from the & sir.

begin. may sir, open line is you Your

Doug Schenkel

follow-up million good want Okay. in Thank China. the to I stocking afternoon. $XX you order and on

fundamental if with NovaSeq First, And Third, for how the much happened couple to lastly know the of not this is attributable to NovaSeq? probably China a and adjusted why? it's stocking how and so, consumables? do Thanks, Second, seeing given most of this utilization it's queue. you see increase And are you back only are confidently in an row? in bulk importantly, orders, globally? quarters get you continuing I’ll in a demand, for

Sam Samad

Yes.

a start, Doug, tariffs by little bit I'll about activity. So, the talking

year. QX the was had last mentioned was we a as between we QX. in mix That we was in later And $XX that QX So, million accelerated and quarter, believe QX. as that accelerated in Chinese we that million into remarks, mentioned on And just the was handful again QX, accelerated is QX. $XX customers. of That I've a from prepared then had from

ahead Our are intel that the really that. concern a concern on of and so fact the that ahead definitely point consumables there tariffs to tariffs, do -- our around might pre-buying be discussions additional these of

entirely In of terms would all the say NovaSeq, large but those, not of -- a a of good proportion they're is them mix I proportion NovaSeq.

of as orders of proportion you terms me did In were placed just that context. give of let a So, there of just that QX, instruments. tariffs whole, some to and in NovaSeq. large bit clarify, said, as on X% believe we are we well But notification those backdrop as were little I tariffs, that, receive a

been hasn't the consumables. There on that's tariffs placed anything only have our been been that that's on So, products. placed

has of know been been advancing in little placed that some been have we a tariffs. amount, potential anything cautious been there's and China on That's customers instruments. X% obviously, still on there But purchases a bit not So, that's ahead and consumables. modest else announced

easily redirected. investments definitely As not I've is mentioned a sequencing commitment before, in -- again, and sequencing

materially tariff, So, changes to don't believe this this landscape sequencing. will have still we even commitment that the because with customers

-- our consumables are instruments Our proprietary.

and instruments, landscape, even a changes driver that consumables. a of consumables believe opposed our our sequencing. this is get on I as more commitment definitely, to would so tariffs We work if timing with more the do Our of only there's something placed to say, long-term

Francis deSouza

step to back to at what I said, market. I'll if look a And the just and China Sam Yes. had add take

three been at quarters If that's growth our revenue in year-on-year. XX% you China for approximately first growth look the XXXX, of

XX% ago, growth you it approximately. year period Now, a same was that take if

And last year. faster and business part of is was was growing story it is it's the bigger China than so of effect China. than our bigger last in in it year a And happening tariff that what's small

Sam Samad

one Doug, you that thing, the well. as last question And on asked

million instruments. been and not the All the the of million purchases, we $XX consumables, announced, have $XX

Operator

comes next Leonard may from Sir, you. Thank queue with The question in you begin. Bank. Dan the Deutsche

Dan Leonard

Thank you.

PopSeq we front we of should as business into of could P&L? mindful the about GeL is as we're anything Thanks. leverage And you of rolling be the is thinking about down in cadence off? there thinking So, be terms the on the should XXXX, comment, anything

Francis deSouza

are sequencing sequencing. engaged and fundamental enabler So, population clear I around as driving sequencing population around precision genomics both in quality of and several the of world the initiatives a publicly genomes that population around If we're look play those XXXX, now are healthcare They going that expect at governments sequencing, to XX,XXX the value all improving out. initiatives its world. of to over of studies of And in year. complete the crossed already out. sort U.K., pioneered though, of the if whole-genome the months, look the the beginning which the In to medicine it's at, dozen we into the there next GeL XXX,XXX it cost area recognizing a initiatives, system we lead population are number things announced coming may they've

that the the XXXX. then be And of And will so they've coming that of entering announced over GeL the next phase will months NHS. driven out into out play

so in genomes. X XXX,XXX will play a Medicine launched May they project. was ready GeL genomes next a Those from from over transition All XX the And Us the what's a big the that's happened for was transition the start ramp-up XXXX. much ramp-up know -- coming we've of there'll talked last of the seen that to GeL. in the that XXXX. though, that That phase that but announced. if opportunity was from in but look expect about $XXX XXXX, I, starting expect and and be period, even, it's Phase you'll progress sequence was the XXXX, around can and vision out the to part the of the Initiative. you U.K. in because few and vision is time, weeks to will a That's over is in the exciting million of out, to U.S., Us that million And to budget $XXX for see very have million to Precision that All million you up in samples you see now, bigger -- message Similarly take years do And as

to the use the Us has got few three the sequencing weeks, are do for of now All XXXX and budget last over going that they've to so selected genotyping. they centers genome And the the

sequencing. and UW So, do the to Baylor, they selected Broad,

into see can as you so to get start that roll out And we XXXX.

see project, Yale. in project start with for XXXX. patients, announced is in that funding XXX,XXX medicine million $XX their expected early They've also You'll genome progress secured from large a more than that to they've and

initiative that think many this addition supposed the year. early happen in pilot -- next into that In on, by we there's was of few France will many, to in the initiatives again end are year, we are the it next to go working those many,

on other big So, initiatives the working color ones. are many some of so and as there we're that that's the well, on

Sam Samad

committed And commitment obviously, hasn't what XXXX are and changed. talk But to We're there. with say regards still all leverage about thoughts to Dan, leverage. to I early it's would our projections fundamentally, our leverage, to and is

committed we're We will creating and investments to still make transformational look the still P&L. those. for overall, fundamentally in But leverage

Operator

of Thank question se Bruin you. America. next Derik Bank from The of comes

you sir. line Your is open, may begin

Derik de Bruin

Hi, good afternoon.

Francis deSouza

Hi Derik.

Derik de Bruin

a I if of ones, short So, may. couple

stocking of through just a material then would a just of of is sense following had when trying get and NIH many were burn up to question life a products? reorder they Question the when -- how potentially on this. see good question really goes we on we've would some stocked? what these the of consumables quarters the I'm this So, question, And of shelf -- last through, sort are in year sales Thanks. in just part year those if that cycle, NovaSeqs written grants I'm the throughput of of or been the upgrade And your of over many of NovaSeq? of half coming NovaSeq? funding. sort you've for the an so, is pipeline instrument curious, is I the of of sales bolus have back of -- the seen how guess,

Sam Samad

we So, question, in shelf-life regards the funding the start to maybe Francis question the answer With is I'll Derik and I'll six-month our nine-month range. about to the somewhere -- usually with let research consumables, grants. consumable then

timeframe of of mind -- range to potential in months and expiration. They terms it. nine of is orders in obviously, tariffs, probably ahead say in exceed a out the they'll cannot for keep months placing would and usually So, the terms terms or shelf-life for I six-month in of the six stocking of that or good two

Francis deSouza

the how mean we're Yes. And industry. very, think playing out. is $X out, budgets then use think grants if welcome are with developing obviously I very funding we in the NIH happy increase I a in how was in about budget terms billion the of the going

variety of across genomics-based of work of interesting domains. that's also We to diseases conditions shifting about budget cardiovascular the to academic talked other see studies chronic We in continue neurodegenerative lots a a and happening and to.

to up, So, science envelope for going really see good testing, really of which the good news for we well. not is but the news us is continue to shift budget only budget obviously genomic as and a overall

In grants the they've to for they that's because to changed. here they X. if starting used it certainly, don't but X U.S., see terms last the were continue with TOPMed wanted And to how to running and of are the projects -- they run NovaSeqs, be giving in -- we out done before wanted to know you the recall I that's projects year, it were that still be the

they the HiSeq are We yet before where the at as saw not NovaSeqs with we requiring X. are stage,

they're that transition people winning the those saying, do typically it better have in a the where you in grants. those that So, applying you projects what and and of for just that happens requirement better a becomes yes, think we're fact, economics in terms is have can stages, of next and, chance

Operator

you. comes Mark Thank queue Massaro in question with the Canaccord next from the Genuity. And

line Your open, is begin. you may

Mark Massaro

put seems that consumables XX% recognizing U.K., biopsy can quarter Hey the we average, like The four XX%. sequencing quickly XX questions. of up studies, was that last Us on this growth sequenced. be count for million It liquid with Geisinger, thanks All genomes will you've quarters,

system about is year, population, broad-based when doing as step current Geisinger you systems exome about or should a are of to give talking from sense we a for health their should sequencing materially next I As think then Francis, if a can IDNs question, on people? sequencing that there levels? say, related this why you any clinical part And down to to particular reason think us or consumables we -- second health other do sequencing exome

Francis deSouza

Yes.

unusual thing. can say nothing a year the think that have about lot just or quarters, So, temporal of there's given those to growth in past for thing maybe trends but point to the are secular not sequencing timing thing. the demand just here if have I last an stay. rate And the that things in was consumables a quarter They're and previous that I us that XX%-plus driven

year, all transition going NIPT out. So, have poised go this biopsy, to future, people for trend and that may sequencing side, tests. into grow the It's force to going But example, scale that to to week. doing running terms full point a trends There those it's up GeL drove population that at liquid more of the demand whether was on NHS. be of are NIPT right? into We're going in this every plays I almost the can

from today, and lung liquid test biopsies, the got was liquid for local GuardantXXX, around coverage It non-small So, cancer really reimbursement Palmetto. we the biopsy saw that get and it's cell the exciting decision not first.

biopsy, you And expect to there of. liquid be so more

like going going sequencing population are They're Trends to over again, are period. secular the trends to trends. out. a play out multiyear So, the play trends

certainly part quarter, What's the this at think looks So, trends. telling durable was next we're I it year, the stage, you're you absolutely it. not second not are particular but These with question? any right. of that secular

Mark Massaro

Exome health Geisinger to sequencing with businesses? other potentially

Francis deSouza

Yes, we absolutely are.

health or part triggered about having of a of their your for genome sequencing So, made be doing in patients the whole system your has couple health millions conversations -- around announcement of the record. the your Geisinger exome exome all

patients So, They can capitated are imagine, that we're have be time. the they patients right been but long where now. announced ones for the are definitely conversations especially they systems, as that from yet, ones the to having health conversations. tend have it has other those a in you or interest leading Nothing triggered system

Operator

question next comes Souda with from Thank Puneet you. Leerink The Partners.

Your line is open.

Puneet Souda

Francis. hi Yes, Thanks.

Francis deSouza

Puneet. Hi

Puneet Souda

Hi thanks.

the or So, next up a leading labs NovaSeq in given question leg mid-tier are the of next up on NovaSeqs I this the XXXX you, and the here have labs bigger year. picked have growth that picking for

said the of delivery have in highlighted taken north are I or XXX so, XXX-plus there or and so the NovaSeq. You've past customers you of that think

throughput instrument upgrade of you move buying Prime NovaSeq? into potentially Do them a you understand to broader S there? labs expect those them the cycle? do you Just buy help how do relevance the labs see you us How new do into lower you Do get expect broader into NextSeq? Or see to NovaSeq? to

Francis deSouza

have the in Sure. I'll we a step the if total. of I majority think back, you us start still front saying by in take is of upgrade

you we've number upgrade of I don't talk a cycle. number a of halfway point off if systems, even over total or the total the And now crossed the I'll think the up of add story. So, customers bit segment little

small the If of cut that's you of -- look at have a majority that but a a them centers, the large high minority true, have NovaSeq. bought them completely NovaSeq, over the throughput to

the implementations for terms an front of us, really cutover. work customers shipments in the story or of in a not to that's terms XXXX so there's in labs, been and so of orders, terms do is in And labs, that XXXX of at And both our core large NovaSeq. labs, to lot a of still smaller end have And we upgrade if still XXXX-plus story. you still of smaller it, yet them that's have, it's that story, but a a look

NovaSeqs, And lot us. two so buy the to expect that in that ones business front one or we a of of still

out the them. And and the are S come which waiting for them that's for Prime, of months will some in coming important

were the SX, came waiting now. in of out are valuation cycle Some right them year a just for and which this earlier

those still all is that us. upgrade add and of so of I'd And the up dynamics, front say you majority in different

Operator

the with UBS. from Brennan queue comes next you. in Thank The Daniel question

line sir, begin. you open may is Your

Daniel Brennan

provide the growth of on that, the And were as point of a about business, on other. you the revenue your number inflecting questions can a I clinical we're mix for at there little and you by between maybe translational think already you to is research that I'm then on a thanks if where growth fronts specifically just Obviously, color few but forward. the given about maybe hoping questions. Francis think Hey wondering how rate today business a customer going any color Thanks. Great. was clinical progress and cited.

Francis deSouza

seen look I we've between at translational of in previous continuing same we've what the research, business if quarters. to breakdown build in it's clinical the consistent So, and seen, the way

seeing previously, to of said revenue. NIPT you strong certainly look to off business. mid That VeriSeq and sort and of are continues be our translational, in business growth clinical we drivers the as So, in we're the at if true. Europe, high the And NIPT our XXs with a NIPT it's percentage of of the clinical launch

things lot expand of the is the That's solution. the are product One NIPT year. to market this the that VeriSeq continuing doing we of there addressable for we're for clearance to work been been a get we've doing

year. see play in start to so you should next And that

oncology of The factors. are our our a other segment. big there, of obviously, number clinical there is And business driver,

liquid biopsy large the have We customers.

to We clinical of that happening the customers have are The of academic out business business. the to to our We the comes oncology a lot work all year. immunotherapy. into of going there, identify see predictors lot that's work the of continue and translational commercial a lot And of a of cancer that immunotherapy are centers. driving those things it next of doing success build around is

Daniel Brennan

NovaSeq retired instruments, kind those demand maybe and of terms Great. regarding how customers to old seeing of have elasticity, And spending upgraded with can just discuss you. of the on the those customers consumables? amongst you from related Illumina their already in are Thank follow-up what you're question just kind high prior one those kind then maybe of of customers that to throughput kind

Francis deSouza

spend in sense, us did, bought anticipate look if research track. the a the customers actually things Yes, that we they it they earnings budget quality buying the And it's at call And as was are with bought were metric touched total we people they the market the for a to customers given for and at to look last ones do, we budget, is our throughput high on is of dynamic want powerful of what little an important reason consumable want the known more one that to And we our as bit a and NovaSeq that a shared NovaSeq. aggregate, look haven't that that the that don't have high So, more at we makes NovaSeq ones demand seeing a they we've world them that yet look look ones we a in the that they us that high can. in throughput doing the And saw because it. And research what that right? the customers. you're most they we and was also we NovaSeq, have intuitively bought a sequencer spending before had than NovaSeq. the at at got we is spend

HiSeq, a do if a a is get they study. they'll powered so can a replace powerful higher And they'll then like instrument what NovaSeq do more to

so put samples to generate science. And higher they'll more quality study the into

as they And so samples use power they study. many take the and can they they'll as have, for that

they less So, NovaSeq. the the out it's that's seeing. have not that that they will by numbers borne use samples And when we're

Operator

in The comes Dan next you. from the queue from Citigroup. Arias question Thank

Your line is open, you sir. may begin

Dan Arias

do in in next me just think Thanks good get kind you a that. feel I'm of labs have getting and need? for Thanks. a maybe in year. you average growth of they if NIPT here. that some with that we step-up afternoon. expectations Good for boxes? testing buy infrastructure market on there's there's big curious the like think whether Francis, need risk do you to along the goes that expansion that a Or capacity kind Do the

Francis deSouza

Sure.

of you If for point the will come is will out, year that think the are think customers. and the I sort In into there a that will things coverage one risk drive of increased of growth where going I adoption about for growth you vectors the NIPT from, U.S., as growth next average and drive think couple NIPT.

to for in for pregnancies. to Medicaid NIPT that have September, of that the the to we're covered first progress example, in the So, progress incremental program make -- risk. Medicaid for percentage Florida access lives In got continuing terms average became NIPT U.S. cover risk of average state we

the NIPT access yet talked that that's I now, of about the XX% will payers year, big of average we that that for we're have progress be came guidelines example, some testing like, made look we played And overall there there. The And move important. the think covered though, payers, lives last them, online in to not And couple if see risk a pregnancies. have United. for big out quarter. continue how We at a over some of -- to are moved at the for we've

look at NIPT. which they've ACOG in So, if average you bulletin withdrawn here the U.S., the their practice question utility XXX, risk of

for precursor now risk And average -- that's sensitivity that pregnancies. risk feel of levels And leaves removal in ACOG as endorsing to indicates in for for them industry their similar actually the and previously XXX NIPT more the very because supportive of high is some pregnancies bulletin. specificity practice XXX the NIPT the a that published

of terms the large come couple as in I think that so that move. And with continue so of those ACOG. have we're making play, bears to progress yet guidelines positive And be into will to

big coverage of the average systems. one average of and the growth the going in driver expansion adoption be it's risk the by -- risk VeriSeq So, of here U.S. continued coverage for of to NIPT the for internationally, then NIPT coverage national pregnancies NIPT And is

adopting And Netherlands, the HDA are is the so and of incremental pregnancies the for Germany if Belgium, value well-contingent in have then we progress to are in And so in covered And German vector of the at big acknowledging going assessment very you making NIPT. for and XXX% Switzerland. just screening in the in look of XX progress we've where Europe, with China. Germany, seen some NIPT NIPT we France, U.K., in Europe diagnostic trisomy publishing be in other terms

China. players in growth done. being market a XX NIPT the the closing across we X-ish We everybody, million see million Today, there, on pregnancies continue million, to year in see X-ish all in

And there's opportunity untapped in still China. an so

So, those drive growth. the things that are will NIPT

Operator

you. next Baird. Thank with Catherine comes question The from Schulte

may ma’am, open is line begin. you Your

Catherine Schulte

us iSeq. in on what Francis the Hi, appreciated of give seeing the seen cases But and can types questions. comments your customers you early are? typical you've the commentary you're anecdotal there more use on the some thanks interest for

Francis deSouza

iSeq, iSeq the the very iSeq are potential today. am role about customers I our will If Sure. say broadly, portfolio. play three look and are that I I'd buying strategic at types for who's it excited of in there buying

telling you a on not the actually was and one, of iSeq a control or up you is the you our fire a step the quality a were gate box what that other us do of library before could on on are terrific They to did something early if with they a NovaSeq dollars part that out want before machines library. of the love any of customers. The thousands ones existing run. were run iSeq first you big Illumina of is a the it fastest. they a to wrong And about spend NovaSeq because they're know are would there tens that surprisingly, of orders And

step terrific it's quick little before that allows you a a run. instrument so NovaSeq QC to And a run do you

to seeing that customers a iSeq support and have lot orders that And understood use of we're for case. so

have today. Another or today, they or set purchase own labs. much the of so sequencing and outsourcing do who the capital sample volume smaller they MiniSeq they're customers but And their customers are to either don't are MiSeq

that so exactly that, very excited customers familiar a that very sequencing of for seeing with And some they're and sequencing. in-house. iSeq accessible And for we're are them, iSeq about bringing is instrument

qPCR iSeq boxes, to that instrument research are that that for genomics long-term just is among going the sequencing. they a those we be is today the may the terrific as role they perfect that market of labs most do to untapped customers; then don't And be play labs all. that sequencing instrument don't segments can think fact, get they don't In market. example, do that today probably open up their have that do, and start tens into thousands of the And is they in this but to buying instrument. the to at sequencing are exciting understand that And largely own

Operator

the in question next The Sachs. comes from you. Goldman queue with Thank Patrick Donnelly

sir. You may begin

Patrick Donnelly

How saw already companies of next in us reception. few thinking opportunity compared the to that market? is for placements are be should we as Thanks. market? in the on over to of biopsy years Great. trials developing in we to and about the pretty raise terms funds Can being the on become liquid where the on just Maybe consumables invest used these a and continue yours recently update space a that strong company customer We you one first dedicated public just market.

Francis deSouza

a really is that oncology market. segment the Yes, in exciting

We of various high-profile are companies are a or seeing in for liquid GRAIL as a that cancer very like journey, now seeing biopsy a in used interested being using biopsy some individuals. liquid screening we're asymptomatic the right? stages So, Freenome tool

And cancer going they're sensitivity to cancer, high for really profile encouraging are is and is samples to get patient in Then has Guardant GRAIL what is after tests from GuardantXXX their and about to results And results And liquid at cancer have And the the it's is that to to that has. especially who exciting hard they're patient stage important for types. used have already encouraging. team of not very seeing really sensitivity different have like specificity population things get doing to the a the being where that they're difficult and the cancer a the using shared test, of like designing you're samples they're be this the cancer. biopsy journey. you're continue lung so we're as to what's at And seeing saying is and with that molecular a people terms specificity test degraded. a it out able identify at And of this able that across really population ASCO be screen. earlier The large, Guardant. bring right are them year companies a

be to to blood that assess looking effectiveness recurrence. a MRD do liquid from also the those is a through so tool as And biopsy for test enabling a is look of for patients. using at to able really Guardant therapy to

was also are now And the created of of the is rather the companies getting some what's lend commercial space those so into biopsy all example than suspect. a screening was universal They're It test. gave Silicon not not liquid for that applications usual Valley and that tissue deliver to being tests cloud. a a cancer suspects. that deliver some liquid just exciting themselves biopsy I usual are company are created the The not biopsy. just that was to new a And are entities especially

better we're for this of so area a lot a And to outcomes liquid investment of biopsy recognition the seeing and into do ultimately, improve promise because enormous patients. poured of there's screens

Operator

Thank you, sir.

Steve Beuchaw That Morgan We more for have one time comes Stanley. question. question from from

Your may you line open, is begin.

Steve Beuchaw

try here. samples out consumer. conversation with growth interesting will I touch and round Well, maybe on run Really letting access that been drivers thanks anchor the relay the leg there. story of number on me the of the different to have for the

advantage If think you advertising year last back, their you in ASHG couple taken think the at about year intensity that Amazon have taken relative down, there taken how as is to Thanks. higher. prices two launched price products two? happened because down, consumer push there talk the a next DTC taken their with or out about Can or the some intensity consumer or a of of of the last in on two years growth, players of year over you a driver the over promotional the their you presentation have been part of it's of number structure

Francis deSouza

an And in it's consumer in genotyped got because a we consumer did that question a last This driven as year in and market to primarily exciting story. glad Ancestry driven point. The the One, XXXX million year, was years of samples inflection year, on, the market the previous see samples started we we And touched -- space on did XXandMe. the launched the by it's U.S. we and more play it just growth XXXX. seen that XX XXXX And It I'm see that was an XXXX, saw in done more market great Yes, seen was a -- when it's big it very And we've touch by forward. other was point in out segment, we've market. we X than we so -- couple things a primarily but going combined. market a the we've genealogy in the it in in we inflection sequence in are play primarily story, large players and out. that inflection continued emerge to space. players

large the in And that And tracking from talked about to companies for Southeast revenue we the as of contribution around see we so a example, I world. DTC are are number it, show Asia. up, space now started

We're reports early I if that. a the more the been of really, we're frankly, in definitely the we're the it, said at at happened global really, seeing U.S. for genomics, So, be discoveries the broadening to right? has customers. stages stages DTC genealogy, that now enabled And story it starting see it stages Frankly, a and more become of it so of we're generated outside also of U.S. the to very first ever consumer at have the early drivers of we're have early driver and for than was the,

it also really XXXX. out so the expanded excited in to of And growth that and next be. than story fitness genealogy. some future in segments the years, Helix to wellness, -- coming are for it, of for health where that's out reports genomics we is XXXX. opportunity to of revenue and that's idea to the It's continue showed the but it's consumer the the innovation come vector nutrition, continue it's from pool And about traits, potential try expect figure it's We're up now in consumers and from expand that broader different and could enable to

those so consumer that genomics up. around dynamics have And showed and are the

early now across but of terms of diverse genealogy. more number Board. it of much It's doing they are a driven of the to It's growth continue much targeting, We and interested very that in in the are that segments by see number global a customers story. more

Operator

the Ross Thank remarks. call to Jacquie back for any you. over I'll turn now closing

Jacquie Ross

Thank you.

you a a the update quarter. next be our we a our us the today. call, call forward available for of fourth the reminder, This of webcast replay will website. Thank in following concludes joining As this and of our close section look as Investors

Operator

you ladies gentlemen. today's concludes Thank for you, and participating. Thank This conference.

You may now disconnect.

Illumina (ILMN) 24 Oct 182018 Q3 Earnings call transcript